The earliest pivotal CAR-T trial for R/R DLBCL, utilizing CD19-targeted CAR-T with CD28 costimulatory domain. The ZUMA series has advanced to ZUMA 9 and real-world research, enrolling over 295 patients. Key findings: CD28-based CAR-T triggers rapid, severe cytokine release syndrome (CRS); 32% of patients required ICU admission for CRS. Re-administering identical CAR-T cells to partial response (PR) patients fails to boost efficacy.

Genetic testing is indispensable for hematological disease management. For acute leukemia, it supports diagnosis, prognosis assessment and treatment guidance. However, interpreting genetic mutation reports is highly complex. Clinicians must distinguish germline (inherited) mutations from somatic tumor-derived variants, clarify whether germline variants contribute to leukemia susceptibility, analyze mutation loci, variant combinations, and their impacts on prognosis and target

Genetic testing plays a vital role in diagnosing and treating hematologic malignancies. It enables precise disease classification, prognostic stratification, and personalized treatment planning, guiding targeted therapies and minimizing adverse reactions. By detecting gene mutations and monitoring minimal residual disease (MRD), it helps assess relapse risks and improve patient outcomes.

MICM integrated diagnosis covers Morphology (M), Immunology (I), Cytogenetics (C) and Molecular biology (M), serving as the core diagnostic system for hematological malignancies. Its updated scope also incorporates two additional P modules: Pathogen detection and Pharmacogenomics (MICM-PP). Director Tong Chunrong from Beijing Boren Hospital elaborates on how this integrated system enables precise subtyping and individualized therapy for blood cancers.

Wondering why leukemia patients need genetic testing? Director Zheng Qinlong explains its vital role in precision hematology care. Genetic heterogeneity drives varied chemo responses; gene sequencing guides targeted therapy, MRD surveillance and risk stratification. Comprehensive molecular profiling avoids ineffective regimens, cuts costs and enables personalized long-term treatment plans.

Clinical evaluations are systematically carried out centered on five core laboratory divisions (naming varies across hospitals): Cell Morphology Laboratory, Pathological Diagnosis Laboratory, Flow Cytometry Laboratory, Cytogenetics Laboratory, and Molecular Diagnosis Laboratory. Corresponding tests include cell morphology and cytochemical staining, pathology and immunohistochemistry, flow cytometry, karyotype analysis, FISH, gene testing, etc.

Many patients wonder: How long can CAR-T therapy last? Its long-term efficacy depends not only on the initial anti-tumor effect but also on the persistence of CAR-T cells in the body. Factors like T-cell quality, production process, tumor immune escape, and standardized whole-process management all affect outcomes. To improve durability, doctors recommend early intervention, optimized cell preparation, personalized targets, and long-term monitoring.

China’s first foreign patient treated with axicabtagene ciloleucel CAR-T therapy has been discharged from Shanghai Jiahui International Hospital. A Singaporean mother with refractory lymphoma chose Jiahui for its world-class care, shorter wait and lower cost vs Western countries. Supported by a full MDT team, she recovered smoothly, marking a milestone for China’s international CAR-T treatment.

In early September this year, 74-year-old Ms Bao suffered an abrupt health crisis. Within just a few days, her condition deteriorated rapidly from general fatigue to acute kidney failure. The culprit was atypical hemolytic uremic syndrome (aHUS). Fortunately, thanks to precise treatment by a multidisciplinary team at Sir Robert Run Shaw Hospital, Zhejiang University School of Medicine, she was successfully weaned off dialysis on the 22nd day of onset and regained a healthy li

Excess neck fat acts like a “noose,” compressing the airway. At night, relaxed muscles cause repeated airway collapse: breathing pauses hundreds of times nightly, up to 50 seconds each — repeated cycles of hypoxia → suffocation → awakening. This intermittent nighttime hypoxia: Raises heart workload，Triggers sympathetic overactivity，Causes nocturnal hypertension and arrhythmias，Increases sudden‑death risk.

According to statistics from the Particle Therapy Co‑Operative Group (PTCOG), by 2021, more than 260,000 patients worldwide had received proton or heavy‑ion therapy. The number of proton centers grew from 1 in 1990 to over 100 today, and is still rising rapidly. Proton therapy has become a major global trend in precision cancer radiotherapy.

Recently, a delegation from Bangkok Hospital visited Jiahui Health, and the two sides held exchanges focusing on oncology diagnosis, treatment and innovation. The two sides focused on cutting-edge topics in clinical oncology – ranging from surgical operations to advanced and sophisticated therapies such as CAR-T, as well as the application practice of new anti-tumor drugs in China.

During the treatment, Dr. Chen Yan, Director of the Neurology Department at Jiahui, also addressed several Parkinson’s disease-related issues for Daniel: adjusting his medications, preventing fall risks and formulating a rehabilitation plan. These problems,which had never been properly managed during his treatment in the US, received meticulous attention at Jiahui.

Novel cell therapy shows potential: As an emerging cellular immunotherapy method, CAR-NK cell therapy can still be effective in patients who have failed CAR-T treatment. With mild CRS (cytokine release syndrome) reaction and good safety, it provides a new treatment option for refractory and relapsed patients and is expected to become an important treatment direction for such patients in the future;

Recently, the international hematology journal Blood Advances published a prospective clinical study by Lu Daopei Medical Team, titled "Efficacy and safety of BCMA nanobody CAR T-cell therapy in relapsed or refractory plasma cell myeloma," reporting breakthrough clinical results of BCMA-targeted nanobody-based CAR-T cell therapy in heavily pretreated refractory/relapsed plasma cell neoplasms.